Hye Jin Jeon

Title: Hye Jin Jeon: Innovator in GM1 Gangliosidosis Research

Introduction

Hye Jin Jeon is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the treatment of GM1 gangliosidosis. His innovative approach utilizes induced pluripotent stem cells (iPSCs) to develop a human cell model for this rare genetic disorder.

Latest Patents

Hye Jin Jeon holds a patent for a method related to the treatment of GM1 gangliosidosis. The patent describes a method for preparing a GM1 gangliosidosis human cell model based on iPSCs and neural progenitor cells derived from these iPSCs. This model is crucial for understanding the disease's mechanisms and developing therapeutic agents. The iPSCs, which originate from GM1 patient fibroblasts, can differentiate into neural progenitor cells and neurosphere cells that mimic the characteristics of GM1 patients. This innovative model allows for efficient investigation of intracellular GM1 symptoms and gene expression changes associated with the disease.

Career Highlights

Hye Jin Jeon is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His work has been instrumental in advancing the understanding of GM1 gangliosidosis and developing potential treatments. His research has led to the establishment of the inflammasome inhibitor rhIL1RA or Z-YVAD-FMK, which has shown promise as a therapeutic agent for GM1 gangliosidosis.

Collaborations

Hye Jin Jeon collaborates with notable colleagues, including Yee Sook Cho and Mi Young Son. Their combined expertise enhances the research efforts in the field of GM1 gangliosidosis and contributes to the development of effective treatments.

Conclusion

Hye Jin Jeon's innovative work in developing a human cell model for GM1 gangliosidosis represents a significant advancement in biotechnology. His contributions are paving the way for new therapeutic strategies to combat this challenging disease.